Boston, MA 06/09/2014 (wallstreetpr) – Well Point Inc (NYSE:WLP) is on its verge of initiating an innovative quality affiliated health plan which will enable oncologist to compare the procedures of planned cancer treatment with evidence based cancer treatment. This initiative will be put into practice from the commencement of July, 2014 and will enhance the output from the oncologists. This will be a boon in eradicating cancer from the society. The oncologists will in turn be privileged with enhanced reimbursements.
Approaches in cancer treatment
Along with the sister concern of Well Point Inc (NYSE:WLP), the AIM Specialty Health they identified and incorporated the pathways for cancer treatments based on the existing evidences, medical journals and literatures, predetermined procedures and guidelines and also the policies of Well Point Inc (NYSE:WLP). These are believed to be a pillar for oncologists to help them perform their treatment with greater reliability and eliminate any flaws and delays in early detection. These measures will add a great value to the currently followed measures of curing the tumors.
A glance over the present scenario
- Every third patient receiving the chemotherapy failed to follow a consistent treatment plan that is ruled by medical evidences.
- An increase in 25% of the cancer treatment cost is being observed annually.
- Cancer drugs are flexibly and feasibly purchased directly from the manufacturers or distributors and due to which health insurers reimburse the medical expenses to a higher percentage than the actual cost price.
Areas of implementation
Dr. Jennifer Malin credit this program and proclaimed this program will enhance the reimbursement of the oncologist that prevails due to less expensive drugs. This program will sow its seeds over the geographies of Indiana, Missouri, Kentucky, Wisconsin, Ohio and Georgia with the intent to expand over other parts of America in 2014 and 2015.
The objective of new quality initiative is to reimburse its insurers, either full insurers or self insurers, national accounts members for their visits and cancer drugs regardless of the status of their treatment. Lowering the rate of increasing cost of chemotherapy, increasing affordability and adequately remunerating the oncologists stand forefront to this program.